Halozyme Therapeutics (NASDAQ:HALO) Share Price Breaks Below 50 Day Moving Average – Here’s Why

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $115.19 and traded as low as $102.52. Halozyme Therapeutics shares last traded at $103.63, with a volume of 6,162,578 shares traded.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Tuesday, November 3rd. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a report on Friday. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. HC Wainwright upped their price objective on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $83.00 to $110.00 in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $106.09.

Halozyme Therapeutics Price Performance

The company’s 50 day moving average price is $115.19 and its 200 day moving average price is $84.73. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $11.76 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 0.39 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. The business had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The firm’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same quarter last year, the company posted $1.72 EPS. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 8.32 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 125,852 shares of company stock worth $13,538,046. Insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics in the second quarter valued at approximately $196,540,000. Jupiter Topco LLC acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth $105,570,000. Caisse de depot et placement du Quebec acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth $83,940,000. Finally, Congress Asset Management Co. raised its position in shares of Halozyme Therapeutics by 85.6% during the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock valued at $251,890,000 after acquiring an additional 1,052,509 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.